Overview

Intermittent Androgen Deprivation Therapy With or Without Stereotactic Body Radiotherapy for Molecularly Identified Hormone Sensitive Oligometastatic Prostate Cancer

Status:
Recruiting

Trial end date:
2027-10-01

Target enrollment:

Participant gender:

Summary

This study is evaluating whether adding stereotactic radiotherapy (a new, more focused type of radiotherapy) to treat all the tumours that are present will improve outcomes or not compared to drugs alone for patients who are negative on conventional imaging and positive on PSMA PET scan

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Sunnybrook Health Sciences Centre

Treatments:

Hormones